BACKGROUND AND OBJECTIVES: We studied the relationship between microinflammation and endothelial damage in chronic kidney disease (CKD) patients on different dialysis modalities. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Four groups of CKD stage 5 patients were studied: 1) 14 nondialysis CKD patients (CKD-NonD); 2) 15 hemodialysis patients (HD); 3) 12 peritoneal dialysis patients with residual renal function >1 ml/min (PD-RRF >1); and 4) 13 peritoneal dialysis patients with residual renal function <or=1 ml/min (PD-RRF <or=1). Ten healthy subjects served as controls. CD14(+)CD16(+) cells and apoptotic endothelial microparticles (EMPs) were measured by flow cytometry. Serum vascular endothelial growth factor (VEGF) was measured by ELISA. RESULTS: CKD-NonD and HD patients had a higher percentage of CD14(+)CD16(+) monocytes than PD groups and controls. CD14(+)CD16(+) was similar in the PD groups, regardless of their RRF, and controls. The four uremic groups displayed a marked increase in apoptotic EMPs and VEGF compared with controls. Apoptotic EMPs and VEGF were significantly higher in HD patients than in CKD-NonD and both PD groups. However, there were no significant differences between CKD-NonD and the two PD groups. There was a correlation between CD14(+)CD16(+) and endothelial damage in CKD-NonD and HD patients, but not in PD and controls. CONCLUSIONS: There was an increase in CD14(+)CD16(+) only in CKD-NonD and HD patients. In these patients, there was a relationship between increased CD14(+)CD16(+) and endothelial damage. These results strongly suggest that other factors unrelated to the microinflammatory status mediated by CD14(+)CD16(+) are promoting the endothelial damage in PD, regardless of their RRF.
BACKGROUND AND OBJECTIVES: We studied the relationship between microinflammation and endothelial damage in chronic kidney disease (CKD) patients on different dialysis modalities. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Four groups of CKD stage 5 patients were studied: 1) 14 nondialysis CKD patients (CKD-NonD); 2) 15 hemodialysis patients (HD); 3) 12 peritoneal dialysis patients with residual renal function >1 ml/min (PD-RRF >1); and 4) 13 peritoneal dialysis patients with residual renal function <or=1 ml/min (PD-RRF <or=1). Ten healthy subjects served as controls. CD14(+)CD16(+) cells and apoptotic endothelial microparticles (EMPs) were measured by flow cytometry. Serum vascular endothelial growth factor (VEGF) was measured by ELISA. RESULTS: CKD-NonD and HDpatients had a higher percentage of CD14(+)CD16(+) monocytes than PD groups and controls. CD14(+)CD16(+) was similar in the PD groups, regardless of their RRF, and controls. The four uremic groups displayed a marked increase in apoptotic EMPs and VEGF compared with controls. Apoptotic EMPs and VEGF were significantly higher in HDpatients than in CKD-NonD and both PD groups. However, there were no significant differences between CKD-NonD and the two PD groups. There was a correlation between CD14(+)CD16(+) and endothelial damage in CKD-NonD and HDpatients, but not in PD and controls. CONCLUSIONS: There was an increase in CD14(+)CD16(+) only in CKD-NonD and HDpatients. In these patients, there was a relationship between increased CD14(+)CD16(+) and endothelial damage. These results strongly suggest that other factors unrelated to the microinflammatory status mediated by CD14(+)CD16(+) are promoting the endothelial damage in PD, regardless of their RRF.
Authors: F Maduell; J J Sánchez-Canel; J A Blasco; V Navarro; A Ríus; E Torregrosa; M T Pin; C Cruz; J A Ferrero Journal: Nefrologia Date: 2006 Impact factor: 2.033
Authors: Chantal M Boulanger; Nicolas Amabile; Alain P Guérin; Bruno Pannier; Aurélie S Leroyer; Clément Nguyen Ziad Mallat; Alain Tedgui; Gérard M London Journal: Hypertension Date: 2007-02-19 Impact factor: 10.190
Authors: Wendy P J den Elzen; Jeannette G van Manen; Elisabeth W Boeschoten; Raymond T Krediet; Friedo W Dekker Journal: Nephrol Dial Transplant Date: 2006-01-31 Impact factor: 5.992
Authors: R Ramirez; J Carracedo; A Merino; S Nogueras; M A Alvarez-Lara; M Rodríguez; A Martin-Malo; C Tetta; P Aljama Journal: Kidney Int Date: 2007-04-11 Impact factor: 10.612
Authors: Eva Schepers; Erica Houthuys; Annemieke Dhondt; Grim De Meyer; Nathalie Neirynck; Pascale Bernaert; Rafael Van den Bergh; Peter Brouckaert; Raymond Vanholder; Griet Glorieux Journal: PLoS One Date: 2015-04-01 Impact factor: 3.240
Authors: Fabiany da C Gonçalves; Franka Luk; Sander S Korevaar; Rachid Bouzid; Ana H Paz; Carmen López-Iglesias; Carla C Baan; Ana Merino; Martin J Hoogduijn Journal: Sci Rep Date: 2017-09-21 Impact factor: 4.379
Authors: Serika D Naicker; Sarah Cormican; Tomás P Griffin; Silvia Maretto; William P Martin; John P Ferguson; Deirdre Cotter; Eanna P Connaughton; M Conall Dennedy; Matthew D Griffin Journal: Front Immunol Date: 2018-12-06 Impact factor: 7.561